Trial Profile
A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Cetuximab (Primary) ; Irinotecan (Primary) ; Paclitaxel (Primary) ; Sapanisertib (Primary) ; Tovorafenib (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors Takeda Oncology
- 03 Aug 2018 Status changed from recruiting to completed.
- 08 May 2018 Planned End Date changed from 23 Dec 2017 to 23 Dec 2018.
- 08 May 2018 Planned primary completion date changed from 23 Dec 2017 to 23 Dec 2018.